Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
MicroPort NeuroScientific Total Current Liabilities Related Terms
MicroPort NeuroScientific Total Current Liabilities Historical Data
* Premium members only.
The historical data trend for MicroPort NeuroScientific's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroPort NeuroScientific Total Current Liabilities Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of HK$275.6 Mil mean?
MicroPort NeuroScientific (HKSE:02172) has a Total Current Liabilities of HK$275.6 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for MicroPort NeuroScientific and its competitors.
Is MicroPort NeuroScientific's Total Current Liabilities too high?
MicroPort NeuroScientific's current Total Current Liabilities is HK$275.6 Mil. Overall, MicroPort NeuroScientific has a GF Score™ of 93/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MicroPort NeuroScientific's Total Current Liabilities compare to ABT and SYK?
MicroPort NeuroScientific's Total Current Liabilities of HK$275.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for MicroPort NeuroScientific and its competitors. MicroPort NeuroScientific's current Total Current Liabilities is HK$275.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroPort NeuroScientific stock overvalued right now?
Based on GuruFocus' analysis, MicroPort NeuroScientific (HKSE:02172) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.19, compared to a current price of HK$9.01 — trading 31.7% below its estimated fair value. The current Total Current Liabilities is HK$275.6 Mil. MicroPort NeuroScientific's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For MicroPort NeuroScientific (HKSE:02172), the current Total Current Liabilities is HK$275.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroPort NeuroScientific (HKSE:02172) Overvalued in 2026?
Based on GuruFocus' analysis, MicroPort NeuroScientific stock appears to be undervalued.
The current stock price of HK$9.01 is trading 31.7% below its estimated GF Value™ of HK$13.19.
GuruFocus considers MicroPort NeuroScientific to be Possible Value Trap.
Key valuation signals for HKSE:02172:
Total Current Liabilities: HK$275.6 Mil
GF Value™: HK$13.19 vs. price of HK$9.01 (31.7% below fair value)
No single metric tells the full story. See the HKSE:02172 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroPort NeuroScientific Corp is in the neuro-interventional medical device industry, dedicated to providing solutions for physicians and patients. The company boasts a comprehensive portfolio of approved therapeutic products covering all of three main areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. The company generates almost all of its revenue from the sale of medical devices. Geographically, the company generates the majority of its revenue from the PRC region, and also has operations in Israel.
93GF Score
Get the complete analysis for HKSE:02172
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02172 has been successfully added to your 
